Physician profile
Thomas Duffy
NPI 1275113797
$676.93
in general payments reported to CMS, 2019-2025
16 companies · $40.11 in 2025
The $40.11 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $91.81 · 2023: $217 · 2024: $328 · 2025: $40.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $204.45 | 2022-2024 | Vraylar, Mavyret |
| Nestle Healthcare Nutrition INC. | $96.52 | 2023 | |
| Dexcom, INC. | $83.10 | 2024 | Dexcom G7 Gss (161) |
| Lilly USA, LLC | $31.79 | 2022-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $27.02 | 2022 | |
| Corium, LLC | $26.56 | 2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $25.66 | 2025 | Uzedy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.89 | 2023 | Jardiance |
| Neurocrine Biosciences, INC. | $23.75 | 2024 | Ingrezza |
| Evofem Biosciences, INC. | $23.11 | 2024 | |
| Ucb, INC. | $22.35 | 2024 | Rystiggo |
| Amgen INC. | $20.94 | 2022 | |
| Pfizer INC. | $18.90 | 2023 | |
| Xeris Pharmaceuticals, INC. | $18.34 | 2024 | Gvoke Hypopen |
| Alkermes, INC. | $16.06 | 2024 | Vivitrol |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.49 | 2023 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Duffy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.